ArticleCureus2026
Serological and Clinical Evaluation of Incompatible Crossmatches Encountered in Pre-transfusion Testing.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Pre-transfusion testing is essential for preventing incompatible red cell transfusions and associated adverse reactions. Despite modern serological advancements, unexpected alloantibodies, autoantibodies, and monoclonal antibody interference continue to contribute to incompatible crossmatches. This study evaluates the serological patterns, clinical associations, and diagnostic considerations of incompatible crossmatches encountered in routine transfusion practice. Methods This cross-sectional study was conducted at a tertiary-care transfusion service of Swami Rama Himalayan University, Dehradun, India, over a duration of 18 months, from April 2023 to September 2024. Of 34,631 packed red blood cell (PRBC) crossmatches performed, 46 (0.13%) showing major incompatibility were included. Detailed clinical history, hematological parameters, and immunohematological testing, including Direct Coombs Test (DCT), Indirect Coombs Test (ICT), extended antibody panels, and daratumumab interference assessment, were performed. Associations between antibody category and clinical variables were analyzed using Chi-square/Fisher's exact tests, with p < 0.05 considered significant. Results Among 46 incompatible crossmatches, alloantibodies were the most frequent antibody type (24; 52.1%), followed by autoantibodies (16; 34.8%) and daratumumab interference (6; 13.0%). DCT status showed a significant association with antibody type (p = 0.001), with autoantibodies observed exclusively in DCT-positive cases (16/16; 100%), while daratumumab interference occurred only in DCT-negative cases (6/6; 100%). Significant associations were observed for age group (p = 0.012), clinical diagnosis (p = 0.001), previous transfusion history (p = 0.001), number of PRBC units transfused (p = 0.001), hepatomegaly (p = 0.009), and splenomegaly (p = 0.001). Younger patients predominantly exhibited alloantibodies, whereas patients older than 50 years showed contributions from all antibody categories. Autoantibodies predominated in benign hematological disorders (12; 75.0%), while daratumumab interference was confined to hematological malignancies (6; 100%). Gender (p = 0.463) and Rh typing (p = 0.076) were not significantly associated with antibody distribution. Logistic regression analysis did not identify reliable independent predictors due to wide confidence intervals and model instability. Conclusion Most incompatible crossmatches were caused by alloantibodies, though clinically significant contributions from autoantibodies and daratumumab interference were also observed. Strong associations with demographic and diagnostic variables highlight the importance of individualized immunohematological assessment. Routine use of structured diagnostic algorithms can enhance resolution of incompatible crossmatches and strengthen transfusion safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.